{{Rsnum
|rsid=6917207
|Gene=AKAP7
|Chromosome=6
|position=131149096
|Orientation=plus
|GMAF=0.2746
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=AKAP7
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 69.9 | 26.5 | 3.5
| HCB | 15.3 | 49.6 | 35.0
| JPT | 26.5 | 55.8 | 17.7
| YRI | 89.7 | 10.3 | 0.0
| ASW | 75.4 | 24.6 | 0.0
| CHB | 15.3 | 49.6 | 35.0
| CHD | 12.8 | 42.2 | 45.0
| GIH | 26.7 | 53.5 | 19.8
| LWK | 99.1 | 0.9 | 0.0
| MEX | 56.9 | 37.9 | 5.2
| MKK | 87.8 | 12.2 | 0.0
| TSI | 60.8 | 35.3 | 3.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs6917207
|Name_s=
|Gene_s=AKAP7
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: T, MAF= 0.16, combined P value= 8.02E-05.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470180
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6917207
|overall_frequency_n=36
|overall_frequency_d=128
|overall_frequency=0.28125
|n_genomes=21
|n_genomes_annotated=0
|n_haplomes=29
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}